ALNYLAM							
Study name	**Objective**	**Major Inclusion criteria**	**Major Exclusion criteria**	**Centers in Europe**	**Major time points**	**Status**	**More information**
002 OLE STUDY	Phase 2 long-term safety and tolerability of lumasiran in patients with PH1	-≥6 Years of age -Confirmation of PH1 diagnosis -Estimated glomerular filtration rate (GFR) of >45 mL/min/1.73m^2	-Abnormal AST and ALT and any other significant clinical safety laboratory result -Known history of allergic reaction to an oligonucleotide or N-acetylgalactosamine (GalNAc)	**France** (Bordeaux**,** Lyon**,** Paris) **Germany** (Bonn) **NL** (Amsterdam) **UK** (Birmingham**,** London)	-up to 22 months study data presented in Oct 2020 -Estimated Study Completion Date June 2023	Recruitment completed active follow-up	https://www.clinicaltrials.gov/ct2/show/NCT03350451?term=Lumasiran&draw=2&rank=5
003 ILLUMINATE A	Phase 3 efficacy and safety of Lumasiran in Children and Adults PH1	-Confirmation of PH1 disease -Meet the 24-hour urine oxalate excretion requirements	-An estimated GFR of < 30 mL/min/1.73m^2 -Clinically significant abnormal laboratory results	**France** (Bordeaux**,** Lyon**,** Paris) **Germany** (Bonn) **NL** (Amsterdam) **Switzerland** (Bern) **UK** (Birmingham**,** London)	-12 months study data presented in Oct 2020 -Estimated Study Completion Date January 2024	Recruitment completed active follow-up	https://www.clinicaltrials.gov/ct2/show/NCT03681184?term=Lumasiran&draw=2&rank=4
004 ILLUMINATE B	Phase 3 efficacy, safety, pharmacokinetics and pharmacodynamics of lumasiran in infants and young children with PH1	-Confirmation of PH1 disease -Meet the 24-hour urine oxalate excretion requirements	-Abnormal serum creatinine levels for infants who are < 1 year old -No relatively preserved kidney function -Clinical evidence of systemic oxalosis	**France** (Bordeaux**,** Lyon**,** Paris) **Germany** (Bonn) **UK** (Birmingham**,** London)	-6 Months study data presented in Oct 2020 -Estimated Study Completion Date July 2025	Recruitment completed active follow-up	https://www.clinicaltrials.gov/ct2/show/NCT03905694?term=Lumasiran&draw=2&rank=2

005 ILLUMINATE C	Phase 3 efficacy, safety, pharmacokinetics and pharmacodynamics of lumasiran in patients with Advanced PH1	-documented diagnosis of PH1 -eGFR ≤45 mL/min/1.73 m^2 for patients ≥12 months of age (<12 months of age, creatinine elevated for age -Meets plasma oxalate level requirements -If on dialysis, on stable hemodialysis	-peritoneal dialysis alone or combined -History of liver and/or kidney transplant	**Belgium** (Brussels) **France (**Bordeaux**,** Lyon**,** Paris) **NL (**Amsterdam) **Switzerland** (Bern) **UK (**Birmingham**,** London)	-6 Months study data expected in 2021 -Estimated Study Completion Date July 2025	Active	https://www.clinicaltrials.gov/ct2/show/NCT04152200?term=Lumasiran&draw=2&rank=1
Expanded Access Program	Expanded access of lumasiran for adults and pediatric patients with PH1	Ask your treating physician	Ask your treating physician	Depending on country local regulations	NA	NA	Ask your treating physician